Add this topic to your myFT Digest for news straight to your inbox
Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS
German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations
‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants
The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven
Remuneration at the three big jab makers reflects surge in value of share options
Drugmakers set to take on GSK as they aim to replicate Covid jab success
Drugmakers are stress-testing existing jabs while preparing new formulas
WHO says differing predictions from Oxford, BioNTech and Moderna are ‘premature’
Rwanda and Senegal agreement a big step in plans to produce Covid jabs on the continent
Results hailed as ‘important’ but duration of protection still unknown
Ugur Sahin says the virus is very likely to mutate and evade immunity given by current jabs
Expected €15.9bn revenues will enable big push into cancer, TB and malaria research
German group behind successful Covid jab hopes to have a vaccine in trials by 2022
New deal for Covid vaccinations comes amid debate over whether Delta variant requires third doses
German biotech plans to build mRNA facilities on the continent in next four years
Ugur Sahin, Kate Bingham, Seth Berkley and Martin Lush talk to the FT about how to improve pandemic responses
Company has tested vaccine it pioneered with Pfizer against more than 30 strains of the virus
BioNTech’s vaccine facility in Marburg will produce 750m doses a year
Chief Ugur Sahin expects existing shot to be effective but it can be tweaked if needed
By developing a Covid vaccine in less than a year, the couple achieved a remarkable scientific and business success
The husband and wife team behind the German company are pioneers in a technology that could transform medicine
Research into the mRNA science underpinning the jab was accelerated by the pandemic
Positive trial data is milestone for experimental products using new mRNA technology
Positive trial results could lead to shot being available for use by the end of the year
German group’s treatment is among only 9 candidates to have entered a phase 3 trial
International Edition